文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

基因校正的范可尼贫血患者动员CD34+细胞的植入及体内增殖优势

Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients.
PubMed 文献 · Blood · 2017-08-11

本研究采用经临床验证的短时转导方案,以治疗性FANCA慢病毒载体转导G-CSF联合普乐沙福动员的范可尼贫血A型(FA-A)患者CD34+细胞,体外可纠正造血祖细胞表型;移植入免疫缺陷小鼠后可重复植入髓系、淋系及CD34+细胞,且校正细胞比例较输注移植物明显增加,提示校正的FA-A造血重建细胞具有增殖优势。

要点

  • 短时转导方案可纠正FA-A患者动员CD34+细胞体外造血祖细胞表型。
  • 转导后FA CD34+细胞移植免疫缺陷小鼠可重复植入髓系、淋系及CD34+细胞。
  • 移植后表型校正的患者来源造血细胞比例较输注CD34+移植物明显增加,提示增殖优势。

核心结论

  • 优化采集FA患者造血干细胞并经短时临床验证转导后,可生成表型校正、能在免疫缺陷小鼠中重建并展现增殖优势的造血干/祖细胞。
  • 作者认为类似本研究的FA基因治疗临床方案将促进FA患者基因校正造血干/祖细胞的造血重建,为FA基因治疗开辟新前景。
  • 原文结论使用suggest语气,认为类似方案将facilitate造血重建,未给出具体推荐等级。

研究设计与样本

  • 研究采用经临床验证的短时转导方案,以治疗性FANCA慢病毒载体转导G-CSF联合普乐沙福动员的FA-A患者CD34+细胞。
  • 转导后的FA CD34+细胞移植入免疫缺陷小鼠,观察植入情况。
  • 原文未报告样本量、随访时长及研究类型的具体标签。

主要发现

  • 短时转导方案可纠正FA-A患者体外培养造血祖细胞的表型。
  • 转导的FA CD34+细胞移植免疫缺陷小鼠后,可重复植入髓系、淋系和CD34+细胞。
  • 移植后表型校正的患者来源造血细胞比例较输注的CD34+移植物明显增加,提示校正的FA-A造血重建细胞具有增殖优势。
  • 原文称首次证明优化采集联合短时临床验证转导可生成表型校正、具增殖优势的造血干/祖细胞。

关键数值与推荐

  • 原文未报告具体的植入比例、细胞数量、P值或置信区间等数值。

临床怎么用

  • 原文未据此给出临床推荐;作者在结论中认为类似本研究的FA基因治疗临床方案将促进FA患者基因校正造血干/祖细胞的造血重建。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous Fanconi anemia (FA) gene therapy studies have failed to demonstrate engraftment of gene-corrected hematopoietic stem and progenitor cells (HSPCs) from FA patients, either after autologous transplantation or infusion into immunodeficient mice. In this study, we demonstrate that a validated short transduction protocol of G-CSF plus plerixafor-mobilized CD34+ cells from FA-A patients with a therapeutic FANCA-lentiviral vector corrects the phenotype of in vitro cultured hematopoietic progenitor cells. Transplantation of transduced FA CD34+ cells into immunodeficient mice resulted in reproducible engraftment of myeloid, lymphoid, and CD34+ cells. Importantly, a marked increase in the proportion of phenotypically corrected, patient-derived hematopoietic cells was observed after transplantation with respect to the infused CD34+ graft, indicating the proliferative advantage of corrected FA-A hematopoietic repopulating cells. Our data demonstrate for the first time that optimized protocols of hematopoietic stem cell collection from FA patients, followed by the short and clinically validated transduction of these cells with a therapeutic lentiviral vector, results in the generation of phenotypically corrected HSPCs capable of repopulating and developing proliferation advantage in immunodeficient mice. Our results suggest that clinical approaches for FA gene therapy similar to those used in this study will facilitate hematopoietic repopulation in FA patients with gene corrected HSPCs, opening new prospects for gene therapy of FA patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Río P, Navarro S, Guenechea G, et al. Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. Blood. 2017. PMID: 28801449. doi:10.1182/blood-2017-03-774174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。